Melody Cobleigh to Antineoplastic Agents
This is a "connection" page, showing publications Melody Cobleigh has written about Antineoplastic Agents.
Connection Strength
1.553
-
HER2-directed treatment of metastatic breast cancer: unanswered questions. Oncology (Williston Park). 2013 Mar; 27(3):176, 178, 180.
Score: 0.371
-
Targeting metastatic and advanced breast cancer. Semin Oncol Nurs. 2007 Feb; 23(1):37-45.
Score: 0.244
-
Is trastuzumab every three weeks ready for prime time? J Clin Oncol. 2003 Nov 01; 21(21):3900-1.
Score: 0.193
-
Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway. Breast Cancer Res Treat. 2019 Sep; 177(2):325-333.
Score: 0.144
-
Olaparib-Induced Severe Folate Deficiency in a Patient With Advanced Ovarian Cancer. J Oncol Pract. 2019 07; 15(7):405-407.
Score: 0.143
-
Cardiovascular Monitoring With Trastuzumab Therapy: How Frequent Is Too Frequent? JAMA Oncol. 2016 Sep 01; 2(9):1123-4.
Score: 0.118
-
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008 Apr 10; 26(11):1810-6.
Score: 0.066
-
Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 2005 Aug; 6(3):240-6.
Score: 0.055
-
A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin Cancer Res. 2004 Mar 15; 10(6):1971-5.
Score: 0.050
-
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002 Feb 01; 20(3):719-26.
Score: 0.043
-
First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. Eur J Cancer. 2001 Jan; 37 Suppl 1:S25-9.
Score: 0.040
-
First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 2001; 61 Suppl 2:37-42.
Score: 0.040
-
Phase II trial of spirogermanium in advanced non-small cell lung cancer. An Illinois Cancer Council Study. Invest New Drugs. 1989 Jul; 7(2-3):223-4.
Score: 0.018
-
Phase II trial of aminothiadiazole in advanced non-small cell lung cancer. Cancer Treat Rep. 1986 Mar; 70(3):417-8.
Score: 0.014
-
A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer. Ann Oncol. 2002 Aug; 13(8):1220-4.
Score: 0.011
-
Endodermal sinus tumor of the mediastinum. Cancer. 1982 Aug 15; 50(4):766-74.
Score: 0.003